COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

Drug treatment of disseminated non small cell lung cancer  (NSCLC) is an actual  issue today.  Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of  gefitinib (G.)  therapy in patients with non operable NSCLC who hase no E...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: S. A. Protsenko, A. V. Rudakova, F. V. Moiseyenko, E. V. Levchenko, D. E. Matsko, A. О. Ivantsov, I. I. Semenov, A. G. Ievleva, N. V. Mitushkina, A. V. Togo, A. V. Novik, E. N. Imyanitov, V. M. Moiseyenko
Formaat: Artikel
Taal:Engels
Gepubliceerd in: Bashkir State Medical University 2017-01-01
Reeks:Креативная хирургия и онкология
Onderwerpen:
non-small-cell lung cancer
gefitinib
cost-efficacy analysis
Online toegang:https://www.surgonco.ru/jour/article/view/111
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
Aanmelden Informatie over reserveringen

Internet

https://www.surgonco.ru/jour/article/view/111

Gelijkaardige items